- Study to evaluate AC101 (HLX22) in combination with anti-PD-1 antibody serplulimab, trastuzumab and chemotherapy in gastric cancer
- Phase 2 comes in addition to ongoing study evaluating AC101 (HLX22) in 1st line gastric cancer in combo with chemo and Trastuzumab, with data expected in Q2 2023
- AC101 (HLX22) was out-licensed to
Shanghai Henlius Biotech for clinical and commercial development inChina on which Alligator is eligible to part of the economics
Alligator out-licensed AC101 (HLX22) to the South Korean company
In
“Henlius is making very encouraging progress in its clinical development of AC101 (HLX22) in gastric cancer," said Søren Bregenholt, CEO ofAlligator Bioscience . “Following the good safety and tolerability results from the Phase 1 study in September, this is now the second Phase 2 study the company has initiated with this candidate in this indication. It is a further boost to the potential of our AC101 (HLX22) asset, and we are particularly looking forward to seeing what results this new combination setting yields, especially as it includes the addition of the anti-PD-1 monoclonal antibody serplulimab.”
Henlius initiated a prior Phase 2 clinical trial to evaluate AC101 (HLX22) in combination with HANQUYOU (trastuzumab) and chemotherapy as a first-line treatment for HER2-positive locally advanced/metastatic gastric cancer patients in
The information was submitted for publication, through the agency of the contact persons set out below, at
© Modular Finance, source